CPA
LCTX icon

Capital Performance Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Capital Performance Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-163
Closed -$148 – 1522
2024
Q3 		$148 Buy
+163
New +$151 ﹤0.01% 2624

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Capital Performance Advisors's LCTX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q4 2024, closing a stake of 163 shares — an estimated $148 sold.

Capital Performance Advisors first reported a position in LCTX in Q3 2024 and held it in 1 quarter. The position peaked at $148 in Q3 2024. 126 funds tracked by Wall St. Rank hold LCTX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Lineage Cell Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 163 Lineage Cell Therapeutics shares in Q4 2024, an estimated $148.
  • Capital Performance Advisors first reported a position in Lineage Cell Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Lineage Cell Therapeutics position peaked at $148 in Q3 2024.
  • 126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.